Cargando…
Osteosclerotic change as a therapeutic response to gefitinib in symptomatic non-small cell lung cancer bone metastasis
BACKGROUND: Despite improvement in the overall survival of patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutation, the effects of EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment on bone metastasis remain unclear. This study investigated radiol...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801654/ https://www.ncbi.nlm.nih.gov/pubmed/36581856 http://dx.doi.org/10.1186/s12890-022-02226-1 |
_version_ | 1784861536621166592 |
---|---|
author | Miyagi, Michihito Katagiri, Hirohisa Murata, Hideki Wasa, Junji Takahashi, Toshiaki Murakami, Haruyasu Harada, Hideyuki Mori, Keita Takahashi, Mitsuru |
author_facet | Miyagi, Michihito Katagiri, Hirohisa Murata, Hideki Wasa, Junji Takahashi, Toshiaki Murakami, Haruyasu Harada, Hideyuki Mori, Keita Takahashi, Mitsuru |
author_sort | Miyagi, Michihito |
collection | PubMed |
description | BACKGROUND: Despite improvement in the overall survival of patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutation, the effects of EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment on bone metastasis remain unclear. This study investigated radiological responses to gefitinib regarding bone metastasis in patients. METHODS: We treated 260 patients with NSCLC and symptomatic bone metastasis. Thirty-seven patients harboring EGFR mutation were treated with gefitinib for more than 30 days and followed up for more than 3 months (GEF group). We performed a retrospective observational study by selecting 36 cases without EGFR-TKI treatment, at least 3 months of follow-up, and at least two radiological evaluations as the control group. We assessed the best overall radiological response, interval from treatment initiation to appearance of a radiological response, and the local response maintenance rate. RESULTS: The best effect in the GEF group was 98% partial response or better, which was significantly higher than the 57% observed in the control group (p < 0.001). The GEF and control groups maintained 83% and 42% local response maintenance rates at one year, respectively (p < 0.001). In the GEF with radiotherapy group, the local response maintenance rate was maintained at 92% at 1 year, while in the GEF without RT group, there was a decrease in the local response maintenance rate from 270 days. CONCLUSION: Gefitinib treatment for bone metastases in patients harboring EGFR mutation resulted in a beneficial osteosclerotic change in most patients. Combined gefitinib and radiotherapy provide long-lasting local control of bone metastases. |
format | Online Article Text |
id | pubmed-9801654 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-98016542022-12-31 Osteosclerotic change as a therapeutic response to gefitinib in symptomatic non-small cell lung cancer bone metastasis Miyagi, Michihito Katagiri, Hirohisa Murata, Hideki Wasa, Junji Takahashi, Toshiaki Murakami, Haruyasu Harada, Hideyuki Mori, Keita Takahashi, Mitsuru BMC Pulm Med Research Article BACKGROUND: Despite improvement in the overall survival of patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutation, the effects of EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment on bone metastasis remain unclear. This study investigated radiological responses to gefitinib regarding bone metastasis in patients. METHODS: We treated 260 patients with NSCLC and symptomatic bone metastasis. Thirty-seven patients harboring EGFR mutation were treated with gefitinib for more than 30 days and followed up for more than 3 months (GEF group). We performed a retrospective observational study by selecting 36 cases without EGFR-TKI treatment, at least 3 months of follow-up, and at least two radiological evaluations as the control group. We assessed the best overall radiological response, interval from treatment initiation to appearance of a radiological response, and the local response maintenance rate. RESULTS: The best effect in the GEF group was 98% partial response or better, which was significantly higher than the 57% observed in the control group (p < 0.001). The GEF and control groups maintained 83% and 42% local response maintenance rates at one year, respectively (p < 0.001). In the GEF with radiotherapy group, the local response maintenance rate was maintained at 92% at 1 year, while in the GEF without RT group, there was a decrease in the local response maintenance rate from 270 days. CONCLUSION: Gefitinib treatment for bone metastases in patients harboring EGFR mutation resulted in a beneficial osteosclerotic change in most patients. Combined gefitinib and radiotherapy provide long-lasting local control of bone metastases. BioMed Central 2022-12-29 /pmc/articles/PMC9801654/ /pubmed/36581856 http://dx.doi.org/10.1186/s12890-022-02226-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Miyagi, Michihito Katagiri, Hirohisa Murata, Hideki Wasa, Junji Takahashi, Toshiaki Murakami, Haruyasu Harada, Hideyuki Mori, Keita Takahashi, Mitsuru Osteosclerotic change as a therapeutic response to gefitinib in symptomatic non-small cell lung cancer bone metastasis |
title | Osteosclerotic change as a therapeutic response to gefitinib in symptomatic non-small cell lung cancer bone metastasis |
title_full | Osteosclerotic change as a therapeutic response to gefitinib in symptomatic non-small cell lung cancer bone metastasis |
title_fullStr | Osteosclerotic change as a therapeutic response to gefitinib in symptomatic non-small cell lung cancer bone metastasis |
title_full_unstemmed | Osteosclerotic change as a therapeutic response to gefitinib in symptomatic non-small cell lung cancer bone metastasis |
title_short | Osteosclerotic change as a therapeutic response to gefitinib in symptomatic non-small cell lung cancer bone metastasis |
title_sort | osteosclerotic change as a therapeutic response to gefitinib in symptomatic non-small cell lung cancer bone metastasis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801654/ https://www.ncbi.nlm.nih.gov/pubmed/36581856 http://dx.doi.org/10.1186/s12890-022-02226-1 |
work_keys_str_mv | AT miyagimichihito osteoscleroticchangeasatherapeuticresponsetogefitinibinsymptomaticnonsmallcelllungcancerbonemetastasis AT katagirihirohisa osteoscleroticchangeasatherapeuticresponsetogefitinibinsymptomaticnonsmallcelllungcancerbonemetastasis AT muratahideki osteoscleroticchangeasatherapeuticresponsetogefitinibinsymptomaticnonsmallcelllungcancerbonemetastasis AT wasajunji osteoscleroticchangeasatherapeuticresponsetogefitinibinsymptomaticnonsmallcelllungcancerbonemetastasis AT takahashitoshiaki osteoscleroticchangeasatherapeuticresponsetogefitinibinsymptomaticnonsmallcelllungcancerbonemetastasis AT murakamiharuyasu osteoscleroticchangeasatherapeuticresponsetogefitinibinsymptomaticnonsmallcelllungcancerbonemetastasis AT haradahideyuki osteoscleroticchangeasatherapeuticresponsetogefitinibinsymptomaticnonsmallcelllungcancerbonemetastasis AT morikeita osteoscleroticchangeasatherapeuticresponsetogefitinibinsymptomaticnonsmallcelllungcancerbonemetastasis AT takahashimitsuru osteoscleroticchangeasatherapeuticresponsetogefitinibinsymptomaticnonsmallcelllungcancerbonemetastasis |